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OBJECTIVES The goal of this study was to develop a device for percutaneous replacement of the tricuspid
valve in animals.
BACKGROUND Percutaneous valve replacement has recently been introduced, and early clinical experience has
been reported. To date, this technique is limited to the replacement of pulmonary and aortic
valves in selected patients.
METHODS A newly designed nitinol stent, forming two large disks separated by a cylinder with a
diameter of 18 mm, was specially designed for the purpose of this study. An 18-mm bovine
valve was mounted in the central part of the stent, and a polytetrafluoroethylene membrane
was sutured onto the ventricular disk. Eight ewes were equally divided into two groups (group
1, acute study; group 2, killed at one month).
RESULTS Seven of eight devices were successfully delivered in the desired position. In one animal,
the device was trapped in tricuspid cordae, leading to its incomplete opening. A
significant paravalvular leak was noticed in one animal of group 2. Mean right atrial
pressure increased from 5 to 7 mm Hg and did not change during the follow-up. At
autopsy, examination confirmed the good position of devices in successfully implanted
animals.
CONCLUSIONS Implantation of a semi-lunar valve in the tricuspid position is possible in ewes through a
transcatheter approach. A disk-based nitinol stent is needed to allow valve implantation in the
atrioventricular position. These studies open new perspectives into tricuspid as well as mitral
valve replacement. (J Am Coll Cardiol 2005;46:360–5) © 2005 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.063of Cardiology Foundation
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eercutaneous valve implantation has been introduced
ecently with promising results (1– 6). Experience is
resently limited to aortic and pulmonary valves. Exten-
ive work has been undertaken to extend indications
o the whole spectrum of aortic and pulmonary valve
iseases as well as to atrioventricular cardiac valves.
arious approaches have been reported in animals to
epair the mitral valve, namely the edge-to-edge or
lfieri repair using an intervascular clip, and the annu-
oplasty through the coronary sinus (7,8). However, to
ate, no transcatheter technique has been described to
eplace mitral or tricuspid valves. To broaden the indi-
ations of percutaneous approach to atrioventricular
alves, we developed a self-expandable stent that allowed:
) downsizing of the diameter of the annulus to the
vailable valve diameter, and 2) device fixation to the
nnulus. We report here our experience with this new
evice in ewes.
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evice description. We designed a self-expandable stent
onstructed from a 0.22-mm nitinol wire (AMF, Reuilly,
rance). It is a symmetrical device with an overall length when
eployed of 15 mm. It is formed by two flat disks and a tubular
ortion. The disks and the central part had a spontaneous
iameter of 40 mm and 18 mm, respectively (Fig. 1A). It is
raided using a single wire, making all parts physically
nterconnected. When deployed, the disks tended to join
n the middle of the tubular part (Fig. 1B). Because of
his design and the alloy properties, the tendency of
pposition of these disks created forces that fixed the
evice around the annulus with one disk being deployed
n the right ventricle (RV) and one in the right atrium
RA). Additionally, the tubular part interconnected be-
ween the disks acted as a supporting structure for the
alve to be implanted.
evice preparation. A naturally valved venous segment,
arvested from the bovine jugular vein (Contegra,
edtronic Inc., Minneapolis, Minnesota) was prepared
s previously reported (1,2) and mounted into the tubular
art of the self-expandable stent. To guarantee the
ealing of the device, we sutured a polytetrafluoro-
thylene (PTFE) membrane, usually used for covered
tents (Zeus Inc., Orangeburg, South Carolina), on the
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as not covered to limit the risk of coronary sinus
cclusion. All devices were stored in glutaraldehyde
olution until their use.
he delivery system. The delivery system consisted of
“homemade” front-loading 18-F long sheath (Cook
nc., Charenton le Pont, France). For the purpose of
he study, the distal tip of a dilator was cut off. A piece
f catheter was fixed to this part to liberate space for
tent placement. The length of this space (i.e., piece
f catheter) was 5.5 cm, which was the length of
he device when in the constrained position. At the tip
f the catheter, a 1-cm-long dilator was attached to
llow for a smooth transition between the tip and the
heath and to facilitate the tracking of the delivery system
uring its course. The sheath could freely slide over the
evice. No balloon was necessary to deliver the nitinol
tent that spontaneously deployed at the time of
ncovering.
reparation of the animals. Animals were treated ac-
ording to the European regulations (9), and the protocol
as approved by the institutional ethics committee. Eight
wes weighing 60 to 70 kg were included. We intended to
mplant in the tricuspid position a device sheltering an
8-mm valve as a one-step procedure. Animals were
ivided into two equal groups according to the killing
ime points. General anesthesia was induced with 10
g/kg of thiopental and maintained with isoflurane.
Abbreviations and Acronyms
PA  pulmonary artery
PTFE  polytetrafluoroethylene
RA  right atrium/atrial
RV  right ventricle/ventricularigure 1. (A, B, C) En face and lateral views of the newly designed stent befo
embrane and the suture of the valve in the central tubular part (C). The stenight jugular and femoral veins were prepared for
atheterization.
ercutaneous replacement of the tricuspid valve. Through
he right jugular vein, a 5-F right Judkins coronary catheter
Cordis, Issy les Moulineaux, France) was advanced in the
istal right pulmonary artery (PA). Through this catheter, a
.035-inch extra-stiff guidewire (Amplatzer, Golden Valley,
innesota) was positioned distally. The valved device was
oaded into the delivery system, inserted over the previously
ositioned wire, and advanced into the RV. As with devices
or closure of atrial septal defects, the distal disk was
eployed in the RV by pulling on the external sheath while
aintaining the dilator in position. This disk was then
pplied to the tricuspid annulus by pulling on the external
heath and dilator. After deployment of the tubular part
ontaining the valve, the second disk was delivered similarly
n the RA (Fig. 2). The two disks sandwiched the annulus,
ith one disk laying into the RV and the proximal one in
he RA.
picardial echocardiography imaging and cardiac
atheterization. The RV and RA pressures were mea-
ured before and after device implantation. Angiographic
valuation consisted of an atrial injection and a right
entriculography. A small left thoracotomy was per-
ormed in all animals to allow for an epicardial echocar-
iography. Angiograms and echocardiography were ini-
ially performed to define the anatomy of the area of
nterest and to measure the maximum diameter of the
ricuspid annulus. Studies were also repeated after im-
lantation and before killing to confirm the appropriate
osition and sealing of the device and to verify the
unction of the implanted valves. In animals with tricus-
id regurgitation, a RV angiography was performed
hrough the RV because the regurgitation could be
nhanced or created by the position of the catheter
hrough the implanted valve.re its covering (A and B), after its covering by a polytetrafluoroethylene
t is shown from the ventricular side with a valve in closed position.
G
(
t
t
t
t
t
a
n
p
a
t
R
T
w
p
i
U
d
a
r
S
d
F
o
i is com
i
362 Boudjemline et al. JACC Vol. 46, No. 2, 2005
Percutaneous Tricuspid Valve Replacement July 19, 2005:360–5raft retrieval. Grafts were electively explanted one hour
group 1) and one month (group 2) after valve implan-
ation. The subvalvular area was examined to determine
he relationship between the cordae and the device and
he position of the implanted device in relation to the
ricuspid valve annulus. After cutting down the interven-
ricular septum, the device was harvested with the RA
nd RV free wall and rinsed to remove excess intralumi-
al blood. Valvular competency was grossly tested by
assing fluid in the graft. The RA was finally dissected
nd inspected macroscopically to look for injuries and for
he position of the proximal disk.
igure 2. Angiograms showing the various steps of device deployment. (A
ver a wire placed in the distal pulmonary artery. (C) The ventricular
s fully opened and applied to the tricuspid annulus. (E) The device
mplanted valve.
Table 1. Measurements Before Replacement o
Ewe Weight (kg)
End-Diastolic Maximu
the Tricuspid Ann
1 62 28
2 60 27
3 66 35
4 64 30
5 60 29
6 65 31
7 60 29
8 64 30RA  right atrial; RVEDP  right ventricular end-diastolic pressESULTS
he mean maximum diameter of the tricuspid annulus
as 30 mm, ranging from 27 to 35 mm. The mean RA
ressure increased from 5 to 7 mm Hg after valve
mplantation (range 4 to 8 mm Hg) (Tables 1 and 2).
nsustained ventricular and atrial ectopic beats occurred
uring wire placement and device deployment in all
nimals. No sustained or hemodynamically relevant ar-
hythmias were recorded during the study.
hort-term evaluation (group 1). In group 1, three of four
evices were successfully implanted with good function of
teral view before valve replacement. (B) The delivery system is advanced
s progressively opened in the right ventricle. (D) The ventricular disk
pletely deployed. (F) Angiogram showing the good function of the
Tricuspid Valve
iameter of
(mm)
Mean RA Pressure
(mm Hg)
RVEDP
(mm Hg)
4 6
3 5
5 6
6 8
5 8
4 7
6 7
3 6) La
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July 19, 2005:360–5 Percutaneous Tricuspid Valve Replacementalves (Table 2). In one animal, it was impossible to
ompletely deploy the valve despite attempts to dilate the
evice with a balloon catheter. In this animal, the device was
ot aligned with the tricuspid annulus. Systemic blood
ressure subsequently decreased, and the QRS enlarged
ith ST-segment depression. Angiographic and echocar-
iographic evaluations showed a severe paravalvular leak. At
utopsy, the ventricular disk was trapped in the tricuspid
ordae, explaining its incomplete deployment. In one ani-
al, the dilator glued on the tip of the delivery system
mbolized in the PA. In another ewe, echographic data
cquired during deployment showed that the ventricular
isk was incorrectly opened in the RA. Because the device
as not fully deployed, it was possible to reload it in the RA
y pushing on the Mullins sheath while maintaining the
ilator and the wire positions. After reloading, the delivery
ystem was re-advanced in the RV and the device was
elivered properly.
ne-month evaluation (group 2). In group 2, all devices
ere successfully implanted. The mean RA pressure did not
ignificantly change when comparing acute and chronic
valuations (7 vs. 7.3 mm Hg). There was no early or late
tent migration (Tables 2 and 3). Evaluations showed that
mplants were in the desired position and confirmed the
ealing of the device, showing no significant leak in three of
our animals (Figs. 2 and 3). In one animal, a significant
aravalvular leak was found at the one-month evaluation. At
utopsy, a pericardial effusion was found and the PTFE was
orn beside a weld fracture. Elsewhere, valves were compe-
ent and no other stent fractures were found. At autopsy,
alve leaflets were thin and mobile in all animals. All devices
able 2. Measurements After Replacement of the Tricuspid Valv
Ewe
mDiam
(mm)
MDiam
(mm)
Mean RA Pressure
(mm Hg)
RVED
(mm H
1 16 18 8 8
2 15 18 4 6
3 17 18 Ventricularized pressure 14
4 14 17 8 8
5 14 18 8 8
6 17 18 7 8
7 15 18 8 8
8 17 18 6 9
he first four animals were included in Group 1.
mDiam  minimum diameter of the tubular part of the device measured during ve
n long-axis view; RA  right atrial; RVEDP  right ventricular end-diastolic pres
able 3. Measurements After One Month in Animals From Gro
Ewe
Mean RA Pressure
(mm Hg)
RVEDP
(mm Hg)
Embolization
of the Device
F
t
5 7 8 No
6 7 6 No
7 Ventricularized pressure 14 No
8 8 8 NoTFE  polytetrafluoroethylene; RA  right atrial; RVEDP  right ventricular end-diasere sitting in the area of the tricuspid annulus. Devices
ere partially covered by a fibrous tissue, making devices
mpossible to retrieve without structural damage (Fig. 4).
o macroscopic damage was noted when inspecting the
ight cavities. As expected, the proximal and distal disks
ere respectively in the RA and the RV. The tricuspid
ative valve was completely inactivated by the stent and
artially retracted.
ISCUSSION
o data are presently available on percutaneous valve
eplacement of atrioventricular valves. Before the availability
f mitral homograft valves, semi-lunar valves were used for
hat indication. For percutaneous implantation the use of
uch valves is possible, but several difficulties must be
esolved. First, the discrepancy between the size of the
vailable transcatheter valve and the size of the annulus
akes the use of current stent designs impossible. Second,
he valve must be anchored to the annulus not to embolize.
hird, in the case of percutaneous reduction of the annulus
ize, the device must ensure the perfect sealing of the gap
etween the true and reduced annulus diameters. Therefore,
t was necessary to develop a device for this indication that
ulfilled the previous criteria. For that purpose, we designed
new self-expandable stent formed of two disks separated
y a tubular part. The diameter of the two disks was chosen
o be slightly larger than the diameter of the tricuspid
nnulus to allow for anchoring. Mechanical fixation was
nsured by trapping the annulus between the two disks. An
8-mm valve was sutured in the tubular part of the device.
Successful Delivery and Placement of
the Device (Number of Attempts)
Echographic and
Angiographic Leak
Yes (1) None
Yes (1) None
No Severe paravalvular leak
Yes (2) None
Yes (1) None
Yes (1) None
Yes (1) None
Yes (1) None
lar systole; MDiam  maximum diameter of the tubular part of the device measured
re of
evice
Echographic and
Angiographic Leak Late Complication
o None None
o None None
s Severe paravalvular leak Loss of 2 kg, pericardial effusion,
tear of the PTFE membrane
o No Nonee
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Percutaneous Tricuspid Valve Replacement July 19, 2005:360–5inally, the PTFE covering guaranteed the sealing of the
evice. The implantation of these newly designed stents was
easible in seven of eight ewes. The implantation of this
ewly designed device permitted the reduction of the
nnulus diameter to the desired diameter with no significant
ncrease in RA pressure. This hemodynamic finding did not
hange in any animals with “late” killing time points. We
ailed to implant one valved device because it was trapped in
he tricuspid cordae. This should be avoided by a more
igure 3. Echographic and schematic views showing the profile of the d
V  tricuspid valve.igure 4. Macroscopic views showing the newly designed valved nitinol stent ex
ides. Note the partial fibrous covering of the nitinol wires and the thin valve iareful echographic assessment before complete release of
he device. Although it has not seemed to be necessary to
ime the delivery of the device in coordination with a
pecific phase of the cardiac cycle, it could be important to
void entrapment in the tricuspid cordae. Techniques of
apid ventricular pacing or vagal stimulation probably
eed to be investigated further. No migration occurred
arly or during the follow-up. A significant paravalvular
eak occurred in one animal. At autopsy at one-month
on the long and short axis. RA  right atrium; RV  right ventricle;planted one month after implantation from ventricular (A) and atrial (B)
nside the stent.
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racture.
tudy limitations and unanswered questions. First, in the
resent study, only animals with a normal tricuspid valve
ere evaluated. In patients with Ebstein anomaly, the
eployment of the device we designed could be hampered
ecause no clear annulus is identifiable between the RA and
he RV. The placement of this stent needs a patent annulus
eparating the two cavities with a larger diameter. Further
evelopments are needed to encompass these difficulties.
he major concern is the risk of myocardial trauma second-
ry to the presence of the stent in regard to cyclic contrac-
ion of the heart. The stent is also submitted to high stress
uring cardiac cycle, which can lead to stent fracture more
requently than in the vascular position. During the overall
tudy, no myocardial complication occurred, but a weld
racture was noticed once at the one-month evaluation.
his fracture led to the tear of the PTFE membrane,
hich further led to a paravalvular leak and progressive
ight heart failure. Long-term studies and bench tests
different from “standard” stents implanted in the vascu-
ar position) will be necessary to address these concerns
ore accurately.
In conclusion, we report here new insights into atrio-
entricular valve replacement using a transcatheter tech-
ique. Further developments and experimental studies
re, however, necessary before considering the use of such
evice in people. This technique could open new per-
pectives into transcatheter replacement of the mitral
alve.cknowledgments
he authors thank Philippe Marx, who developed this
ew stent in cooperation with Younes Boudjemline. We
lso thank Numed and Medtronic Inc. for their technical
upport.
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